Study Title and Description
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).|
|Author||Runowicz CD., Costantino JP., Wickerham DL., Cecchini RS., Cronin WM., Ford LG., Vogel VG., Wolmark N.|
|Country||National Surgical Adjuvant Breast and Bowel Project, National Cancer Institute, Pittsburgh, PA, USA. firstname.lastname@example.org|
Pubmed ID: 21872200
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.